Low dose aspirin for cardiovascular prevention increases risk of bleeding, but absolute risks remain smallBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7570.0-f (Published 28 September 2006) Cite this as: BMJ 2006;333:0-f
Research question What are the bleeding risks associated with antiplatelet agents for cardiovascular prophylaxis?
Answer The absolute risks associated with low dose aspirin are small
Why did the authors do the study? As the population ages, more and more people will need antiplatelet treatment for primary and secondary prevention of cardiovascular disease. These authors wanted to know the absolute increases in bleeding risk associated with low dose aspirin and clopidogrel, the two most commonly used agents, so doctors have clinically relevant information to guide their prescribing.
What did they do? They systematically searched PubMed and the Cochrane Central Register of Controlled Trials for published randomised trials of low dose aspirin (75-325 mg/day) or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial